Descriptions

The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.

Autoinhibitory domains (AIDs)

Target domain

Relief mechanism

Assay

cis-regPred

Accessory elements

No accessory elements

Autoinhibited structure

Activated structure

1 structures for Q5LXC0

Entry ID Method Resolution Chain Position Source
AF-Q5LXC0-F1 Predicted AlphaFoldDB

No variants for Q5LXC0

Variant ID(s) Position Change Description Diseaes Association Provenance
No variants for Q5LXC0

No associated diseases with Q5LXC0

3 regional properties for Q5LXC0

Type Name Position InterPro Accession
conserved_site Fumarate lyase, conserved site 281 - 290 IPR020557
domain Fumarate lyase, N-terminal 12 - 306 IPR022761
domain Argininosuccinate lyase, C-terminal 369 - 437 IPR029419

Functions

Description
EC Number 4.3.2.1 Lyases acting on amides, amidines, etc
Subcellular Localization
  • Cytoplasm
PANTHER Family
PANTHER Subfamily
PANTHER Protein Class
PANTHER Pathway Category No pathway information available

1 GO annotations of cellular component

Name Definition
cytoplasm The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures.

1 GO annotations of molecular function

Name Definition
argininosuccinate lyase activity Catalysis of the reaction: N-(L-arginino)succinate = fumarate + L-arginine.

1 GO annotations of biological process

Name Definition
arginine biosynthetic process via ornithine The chemical reactions and pathways resulting in the formation of arginine (2-amino-5-guanidinopentanoic acid) via the intermediate compound ornithine.

No homologous proteins in AiPD

UniProt AC Gene Name Protein Name Species Evidence Code
No homologous proteins
10 20 30 40 50 60
MTDKTSNQMW GGRFAAGPDA IMEAINASIG FDKRLAAQDI AGSRAHAAML AATGVITDSD
70 80 90 100 110 120
AEAIREGLLT VLSEIEAGEF TFSTALEDIH MNVEARLKEI IGEPAGRLHT ARSRNDQVAT
130 140 150 160 170 180
DFKLWVRDQF DAAEAGLLAL LRALLGQAEA GADWVMPGFT HLQTAQPVTW GHHMMAYVEM
190 200 210 220 230 240
FGRDLSRVRD ARARMNESPL GSAALAGTSF PIDRHMTAAA LGFDRPTANS LDAVSDRDFA
250 260 270 280 290 300
LEFLSVASIC AMHLSRFAEE LVIWSSAQFR FVTLSDRFST GSSIMPQKKN PDAAELIRAK
310 320 330 340 350 360
VGRIFGANTA LMMVMKGLPL AYSKDMQEDK EQVFDAADNW MLALAAMEGM VRDMTANRDS
370 380 390 400 410 420
LAAAAGSGFS TATDLADWLV RVLGLPFRDA HHVTGALVAL AESKGCDLPD LSLDEMQSAH
430 440 450 460
AAITEDVYGV LGVENSVNSR QSYGGTAPAQ VRAQVARWKE MLA